Cargando…
Workshop on immunotherapy combinations. Society for immunotherapy of cancer annual meeting Bethesda, November 3, 2011
Although recent FDA approvals on ipilimumab and sipuleucel-T represent major milestones, the ultimate success of immunotherapy approaches will likely benefit from appropriate combinations with other immunotherapeutic and/or non-immunotherapeutic approaches. However, implementation of ideal combinati...
Autores principales: | Forero, Ivan Martinez, Okada, Hideho, Topalian, Suzanne L, Gajewski, Thomas F, Korman, Alan J, Melero, Ignacio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404934/ https://www.ncbi.nlm.nih.gov/pubmed/22640522 http://dx.doi.org/10.1186/1479-5876-10-108 |
Ejemplares similares
-
Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting
por: Stroncek, David F, et al.
Publicado: (2013) -
29(th) Annual meeting of the Society for Immunotherapy of Cancer (SITC)
por: Hurwitz, Arthur A, et al.
Publicado: (2015) -
The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31(st) anniversary annual meeting
por: Kaufman, Howard L., et al.
Publicado: (2017) -
The future of cancer immunotherapy for brain tumors: a collaborative workshop
por: Brown, Christine E., et al.
Publicado: (2022) -
Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012
por: Sunay, Melek Erdinc, et al.
Publicado: (2013)